Publications by authors named "F Krismer"
Huntington's disease (HD) is a progressive neurodegenerative disorder for which, until now, only symptomatic treatment has been available. Lately, there have been multiple ongoing clinical trials targeting therapeutic agents for preventing disease onset or slowing disease progression in HD. These studies are in constant need of reliable biomarkers for neurodegeneration in HD.
View Article and Find Full Text PDFBackground And Objective: Non-motor symptoms frequently develop throughout the disease course of Parkinson's disease (PD), and pose affected individuals at risk of complications, more rapid disease progression and poorer quality of life. Addressing such symptom burden, the 2023 revised "Parkinson's disease" guideline of the German Society of Neurology aimed at providing evidence-based recommendations for managing PD non-motor symptoms, including autonomic failure, pain and sleep disturbances.
Methods: Key PICO (Patient, Intervention, Comparison, Outcome) questions were formulated by the steering committee and refined by the assigned authors.
Article Synopsis
- Multiple system atrophy (MSA) is a rare, progressive neurological disorder that usually starts in adulthood and features a variety of both motor and non-motor symptoms, often resembling other conditions like Parkinson's disease.
- Research over the past five years has deepened understanding of MSA, particularly regarding the role of α-synuclein inclusions, which are linked to the disease's progression.
- Updated diagnostic criteria in 2022 aim to improve early diagnosis, and while recent clinical trials show promise for new treatments, definitive evidence of neuroprotection is still lacking.
Background: Subthalamic deep brain stimulation (STN-DBS) reduces antiparkinsonian medications in Parkinson's disease (PD) compared with the preoperative state. Longitudinal and comparative studies on this effect are lacking.
Objective: To compare longitudinal trajectories of antiparkinsonian medication in STN-DBS treated patients to non-surgically treated control patients.